INVESTIGATION of EXPRESSION of CTXI LEVELS IN SALIVA WITH EARLY and DELAYED LOADING of DENTAL IMPLANTS

January 30, 2024 updated by: Dania Hamid, Dow University of Health Sciences

INVESTIGATION of EXPRESSION of C-TERMINAL CROSS-LINKING TELOPEPTIDE of TYPE I COLLAGEN(CTXI) LEVELS IN SALIVA WITH EARLY and DELAYED LOADING of DENTAL IMPLANTS

Background:

Implants are commonly used as a treatment choice for partially dentate or in edentulous patients. Currently, no specific biomarker to assess the bone status around the dental implants of healthy patients has been reported to further evaluate bone deposition, resorption and stability. CTX (C-terminal telopeptide) is a known specific biomarker for bone resorption. CTX levels evaluation in serum and urine of patients with bisphosphonates treatment has already been reported. However, its levels in saliva of healthy patients with dental implants has not been investigated, so far.

Objectives:

The aim of this study is to evaluate salivary CTX levels in dental implants with early and delayed loading and to compare it with the values of mechanical stability test (Periotest).

Methods:

Patients coming to OPD of Oral Surgery department of Dow International Dental College (DIDC) and are willing for placement of implant in the posterior molar area of mandible will be enrolled in the study. Informed consent will be taken from each patient for participation in the study. Dental implants placement will be performed according to the standard protocols. All patients will be assessed for implant stability on the day of surgery, at 1 month, 2 month and 3 months by Periotest assessment. Also, saliva will be collected and stored from same patients. Later, ELISA will be performed for expressional analysis of CTX.

Study Overview

Detailed Description

40 Patients coming to OPD of Dow International Dental College for implant placement in posterior mandible (molar area) will be recruited in the study.

Dental implants available in the Outpatient Department (OPD) of Dow International Dental College (DIDC) will be placed in patients. Dental implants will be placed according to the standard protocols by Dr. Shaheen Ahmed.

Patients will be divided in two groups. Group A patients will be early loaded, and group B will be conventional loaded with prosthesis.

Each patient will be evaluated for implant stability after the surgery, at 1 month, 2 months and 3 months with the help of Periotest.

Saliva will be collected from patients in both the groups before placement of implant and on the same days as of Periotest evaluations after surgery. Saliva will be processed and immediately stored at -80oC. Later sandwich ELISA will be performed for expressional analysis of CTX.

Levels of CTX before implant surgery will be served as reference value in this study.

2.9.1 Saliva Collection Method:

Whole unstimulated saliva (WUS) will be collected from both the study groups. The process of saliva collection is as follows:

  • Salivary samples will be collected between 9-11 am to minimize diurnal variations in salivary flow and changes in the sialo chemistry.
  • Patients will be asked to refrain from smoking, drinking and chewing at least one hour before saliva collection to avoid interference of water and food with the analysis.
  • To remove any food debris from mouth, the patients will be asked to wash the mouth with water before saliva collection.
  • After rinsing thoroughly, an interval of at least 10 minutes will be given before the collection of saliva samples to avoid sample dilution.
  • Patients will be asked to spit the saliva in a sterilized falcon tube of 15mL.
  • Approximately 2-5 mL of saliva will be collected from each patient.
  • Patient will be informed and told not to cough up mucus.
  • After saliva collection, samples will be immediately taken to the laboratory for further processing.
  • Salivary samples will be centrifuged at 8000rpm for 15 min at 4˚C to remove any cell debris and supernatant will be collected.
  • The collected supernatant will be aliquoted into microtubes of 1ml and will be stored at -80°C until further analysis (processing time of saliva will be kept lowest as possible).

2.9.2 Salivary Analysis:

Enzyme Linked Immunosorbent Assay (Sandwich Technique):

CTX levels in salivary samples of all the groups will be analyzed by sandwich ELISA (Enzyme Linked Immunosorbent Assay) technique. ELISA testing will be performed by using CTX kit according to manufacturer's instruction. The plate pre-coated with antibody specific to Human CTX will be provided with the kit. Standards or samples are added to the micro ELISA plate wells which allows CTX to bind to its specific antibody. After removing unbound sample, biotinylated CTX detection antibody will be added followed by washing with the buffer. After washing, plate will be incubated with Streptavidin-Horseradish Peroxidase (HRP) that will binds to detection antibody. After incubation, unbound Streptavidin-HRP will be washed away. Finally, substrate solution will be added. The intensity of color developed is proportional to the amount of human CTX present in the sample. The reaction will be stopped by the addition of stop solution and absorbance will be measured spectrophotometrically at 450 nm wavelength. The concentration of CTX in samples is obtained by comparing absorbance of samples to the standards.

ELISA will be performed by principal investigator of the study with the help of her Co-supervisor in DRIBBS (Dow Research Institute of Biotechnology and Biomedical Sciences).

Study Type

Observational

Enrollment (Actual)

40

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Sindh
      • Karachi, Sindh, Pakistan
        • Dania Hamid

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

Patients coming to OPD of Dow International Dental College for implant placement in posterior mandible (molar area) will be recruited in the study.

Description

Inclusion Criteria:

  • Healthy subjects of age 18 and above.
  • Patients who have consented to be part of the study.
  • Patients in whom only posterior mandibular implants are to be placed.

Exclusion Criteria:

  • • Patients with known bone diseases such as osteoarthritis, osteoporosis etc.

    • Patient with uncontrolled diabetes and uncontrolled hypertension etc.
    • Patients who need maxillary implants.
    • Patients treated with oral cancer.
    • Patients who are given implants in fresh extraction sockets.
    • Patients in whom bone augmentation is needed.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
group 1
early loading of dental implants within a month
group 2
delayed loading of dental implants within 3 months

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
c terminal telopeptide of type I collagen
Time Frame: 3 monts
bone resorption biomarker
3 monts

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 10, 2021

Primary Completion (Actual)

October 26, 2022

Study Completion (Actual)

November 18, 2022

Study Registration Dates

First Submitted

January 30, 2024

First Submitted That Met QC Criteria

January 30, 2024

First Posted (Estimated)

February 7, 2024

Study Record Updates

Last Update Posted (Estimated)

February 7, 2024

Last Update Submitted That Met QC Criteria

January 30, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • dowuhs123

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe